MIRUM PHARMACEUTICALS INC
NASDAQ: MIRM (Mirum Pharmaceuticals, Inc.)
Last update: 22 hours ago76.06
1.88 (2.53%)
| Previous Close | 74.18 |
| Open | 74.36 |
| Volume | 439,434 |
| Avg. Volume (3M) | 613,170 |
| Market Cap | 3,821,071,616 |
| Price / Earnings (Forward) | 39.68 |
| Price / Sales | 8.37 |
| Price / Book | 14.54 |
| 52 Weeks Range | |
| Earnings Date | 6 Aug 2025 |
| Profit Margin | -20.39% |
| Operating Margin (TTM) | -13.61% |
| Diluted EPS (TTM) | -1.61 |
| Quarterly Revenue Growth (YOY) | 61.20% |
| Total Debt/Equity (MRQ) | 135.97% |
| Current Ratio (MRQ) | 3.22 |
| Operating Cash Flow (TTM) | -6.85 M |
| Levered Free Cash Flow (TTM) | -23.97 M |
| Return on Assets (TTM) | -7.11% |
| Return on Equity (TTM) | -33.06% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Mirum Pharmaceuticals, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -3.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | 1.00 |
|
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter “IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 1.90% |
| % Held by Institutions | 114.19% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Frazier Life Sciences Management, L.P. | 30 Jun 2025 | 6,795,121 |
| Janus Henderson Group Plc | 30 Jun 2025 | 5,236,277 |
| Bvf Inc/Il | 30 Jun 2025 | 2,761,333 |
| Eventide Asset Management, Llc | 30 Jun 2025 | 2,637,485 |
| Novo Holdings A/S | 30 Jun 2025 | 1,500,055 |
| Clearbridge Investments, Llc | 30 Jun 2025 | 1,027,527 |
| Polar Capital Holdings Plc | 30 Jun 2025 | 975,000 |
| Rock Springs Capital Management Lp | 30 Jun 2025 | 818,206 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 89.00 (Stifel, 17.01%) | Buy |
| 89.00 (Evercore ISI Group, 17.01%) | Buy | |
| Median | 82.00 (7.81%) | |
| Low | 80.00 (HC Wainwright & Co., 5.18%) | Buy |
| Average | 84.20 (10.70%) | |
| Total | 5 Buy | |
| Avg. Price @ Call | 61.06 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Stifel | 11 Aug 2025 | 89.00 (17.01%) | Buy | 65.87 |
| Evercore ISI Group | 08 Aug 2025 | 89.00 (17.01%) | Buy | 59.97 |
| HC Wainwright & Co. | 07 Aug 2025 | 80.00 (5.18%) | Buy | 59.82 |
| JMP Securities | 07 Aug 2025 | 81.00 (6.49%) | Buy | 59.82 |
| Raymond James | 07 Aug 2025 | 82.00 (7.81%) | Buy | 59.82 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 27 Aug 2025 | Announcement | Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences |
| 30 Jul 2025 | Announcement | Mirum Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call on August 6, 2025 |
| 10 Jun 2025 | Announcement | Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |